Gene Therapy Cuts Bad Cholesterol 62% in New Trial

Millions of people fighting high cholesterol may soon have a game-changing option that works with a single treatment instead of daily pills.

Eli Lilly announced results from an early clinical trial showing their gene-editing therapy, VERVE-102, reduced LDL cholesterol (the "bad" kind) by 62% in patients who received the highest dose. This matters because high LDL cholesterol is a major risk factor for heart disease, which remains the leading cause of death worldwide.

The therapy works by editing genes to help the body naturally lower cholesterol levels. Patients received a one-time treatment rather than taking daily medications, which many people struggle to stick with over time.

The Phase 1 study also delivered crucial safety news. Researchers reported no serious treatment-related side effects, a significant finding given that the company's earlier candidate had to be discontinued due to safety concerns.

Lilly acquired the treatment last year when it bought Verve Therapeutics for $1 billion. Company executives believe the therapy could help prevent heart disease on a broad scale, addressing one of medicine's biggest challenges: keeping patients on their cholesterol medications long-term.

Heart disease kills more people globally than any other condition. Current treatments like statins work well but require daily pills that patients often stop taking. Missing doses means cholesterol levels creep back up, increasing heart attack and stroke risk.

The Ripple Effect

A successful one-time treatment could transform how doctors approach heart disease prevention. Instead of relying on patients to remember daily pills for decades, a single intervention could provide lasting protection.

The therapy also represents progress for gene editing as a medical tool. After years of promise and some setbacks, seeing safe and effective results in human trials shows the technology is maturing.

Beyond individual patients, reducing heart disease rates could ease pressure on healthcare systems worldwide. Fewer heart attacks and strokes means fewer emergency room visits, surgeries, and long-term care needs.

This is still early research, and the therapy needs to prove itself in larger, longer studies before reaching patients. But the combination of strong cholesterol reduction and good safety signals gives researchers solid ground to build on as they move forward.